EUVIMEDEUVIMED entdecken
Crossref

Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma

Jinwen Wang, Yaqian Mao, Liantao Li, Jixing Liang, Huibin Huang, Wei Lin, Gang Chen, Junping Wen

Endocrine · 29.05.2024 · 86 (2) · 664-671

DOI: 10.1007/s12020-024-03869-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine, online erschienen am 29.05.2024. Verfasst von Jinwen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical Universi…. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The 2015 American Thyroid Association (ATA) guidelines proposed the use of the ATA Risk Stratification System and American Joint Committee on Cancer Tumor-Node-Metastasis (AJCC/TNM) Staging System for postoperative radioiodine decision-making. However, the management of patients with intermediate-risk differentiated thyroid carcinoma (DTC) is not well defined. In this study, we aimed to evaluate the therapeutic efficacy of radioactive iodine therapy (RAIT) among various subgroups of patients with intermediate-risk DTC after surgery. METHODS: This was a retrospective study based on the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015). The DTC patients with intermediate risk of recurrence were divided into two groups (treated or not treated with radioactive iodine (RAI)). As the treatment was not randomly assigned, stabilized inverse probability treatment weighting (sIPTW) was used to reduce selection bias. We used the Kaplan-Meier method and log-rank test to analyze overall survival (OS) and cancer-specific survival (CSS). RESULTS: Kaplan-Meier analysis after sIPTW found a significant difference in OS and CSS between no RAIT and RAIT (log-rank test, P < 0.0001; P = 0.0019, respectively). The Kaplan-Meier curves of CSS in age cutoff of 55 years showed a significant association between no RAIT and RAIT (log-rank test, P = 0.0045). Univariate and multivariate Cox regression showed RAIT was associated with a reduced risk of mortality compared with no RAIT (hazard ratio [HR] 0.59, 95% confidence interval [95% CI 0.44-0.80]). Age (≥ 55) years showed a worse CSS regardless of whether or not a patient was treated or not treated with RAI ([HR] 8.91, 95% confidence interval [95% CI 6.19-12.84]). CONCLUSIONS: RAIT improves OS and CSS in patients with intermediate-risk DTC after surgery. 55 years is a more appropriate prognostic age cutoff for the relevant classification systems and is a crucial consideration in RAI decision-making. Therefore, we need individualized treatment plans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsHumansFemaleMiddle AgedMaleRetrospective StudiesAdultAgedTreatment OutcomeThyroidectomySEER ProgramYoung Adult

Stichwörter der Autor:innen

ATA risk stratificationDifferentiated thyroid carcinomaRadioiodine therapySEER

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Endocrinology, Key Laboratory of Endocrinology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
  • Department of Internal Medicine, Fujian Provincial Hospital South Branch, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
  • Department of Endocrinology, Key Laboratory of Endocrinology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. caolalin0929@163.com.
  • Department of Endocrinology, Key Laboratory of Endocrinology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. junpingwen@163.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Wang, J., Mao, Y., Li, L., Liang, J., Huang, H., Lin, W., Chen, G., & Wen, J. (2024). Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma. Endocrine, 86(2), 664-671. https://doi.org/10.1007/s12020-024-03869-2

Vancouver

Wang J, Mao Y, Li L, Liang J, Huang H, Lin W, et al. Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma. Endocrine. 2024;86(2):664-671. doi:10.1007/s12020-024-03869-2

BibTeX
@article{Wang2024,
  author = {Wang, Jinwen and Mao, Yaqian and Li, Liantao and Liang, Jixing and Huang, Huibin and Lin, Wei and Chen, Gang and Wen, Junping},
  title = {Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma},
  journal = {Endocrine},
  year = {2024},
  volume = {86},
  number = {2},
  pages = {664--671},
  doi = {10.1007/s12020-024-03869-2}
}
Kostenlos starten →